logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Poly(ADP-Ribose) Polymerase Inhibitor class drugs

    FiltersReset Filters
    5 results

    • akeega

      (NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE)
      Janssen Biotech, Inc.
      Usage: AKEEGA, in combination with prednisone, is indicated for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Treatment selection should be based on an FDA-approved test for AKEEGA.

    • lynparza

      (olaparib)
      AstraZeneca Pharmaceuticals LP
      Usage: Lynparza is indicated for the maintenance treatment of BRCA-mutated advanced ovarian cancer, recurrent ovarian cancer, adjuvant treatment of high-risk early breast cancer, and metastatic breast cancer. Additionally, it treats HRR gene-mutated metastatic prostate cancer, often in combination with other therapies, using FDA-approved companion diagnostics for patient selection.

    • rubraca

      (rucaparib)
      Clovis Oncology, Inc.
      Usage: Rubraca is indicated for maintenance treatment of adult patients with BRCA-mutated recurrent ovarian, fallopian tube, or primary peritoneal cancer responding to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor therapy and taxane chemotherapy.

    • rubraca

      (rucaparib)
      pharmaand GmbH
      Usage: Rubraca is indicated for the maintenance treatment of adults with BRCA-mutated recurrent ovarian cancer in response to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after previous treatments. Selection for therapy should be guided by an FDA-approved companion diagnostic.

    • talzenna

      (talazoparib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: TALZENNA is indicated for treating adult patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. It is also used in combination with enzalutamide for patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).